Financials in USD. Standardized financial statements.
A compact view of how CureVac N.V. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue? | $535.18M | $53.76M | $67.42M | $102.99M | $48.90M | $17.42M | $12.87M |
| Revenue Growth? | +895.5% | -20.3% | -34.5% | +110.6% | +180.8% | +35.3% | 0.0% |
| Cost of Revenue? | $105.83M | $124.37M | $183.99M | $238.19M | $14.17M | $27.98M | $17.74M |
| Gross Profit? | $429.35M | -$70.61M | -$116.57M | -$135.21M | $34.73M | -$10.57M | -$4.87M |
| Gross Margin? | +80.2% | -131.3% | -172.9% | -131.3% | +71.0% | -60.7% | -37.9% |
| Operating Expenses? | $251.67M | $203.60M | $134.28M | $277.06M | $158.70M | $88.93M | $67.95M |
| Operating Income? | $177.68M | -$274.21M | -$249.46M | -$412.26M | -$124.00M | -$99.50M | -$72.82M |
| EBITDA? | $209.69M | -$234.09M | -$209.39M | -$386.49M | -$123.09M | -$93.90M | -$69.85M |
| Income Before Tax | $190.88M | -$259.97M | -$249.16M | -$412.50M | -$129.80M | -$100.13M | -$71.13M |
| Income Tax Expense | $28.70M | $198,000 | -$126,000 | -$782,000 | -$726,000 | -$252,000 | $110,000 |
| Net Income? | $162.19M | -$260.17M | -$249.03M | -$411.72M | -$129.07M | -$99.87M | -$71.24M |
| EPS? | $0.72 | $-1.18 | $-1.32 | $-2.21 | $-0.98 | $-0.53 | $-0.40 |
| Diluted EPS? | $0.72 | $-1.18 | $-1.32 | $-2.21 | $-0.98 | $-0.53 | $-0.40 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality